Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematological Diseases, Non-MalignantHematologic NeoplasmsProtocol groupAcute LeukemiasAnemias, CytopeniasMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)TransplantationDiseaseAcute Lymphoblastic LeukaemiaAcute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic NeoplasmsStem Cell Transplantation, AllogeneicSubgroupDeletion (5q)High riskIDH1-MutationLow riskMDS with elevated blasts -2with Ring SideroblastsICD10C91.0-C92.0-C92.5-C92.6-C92.7-C92.8-C92.9-C93.0-C93.1-D46.-MeSHHematopoietic Stem Cell TransplantationLeukemia, Myelomonocytic, ChronicMyelodysplastic SyndromesPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaTransplantation ConditioningSequenceAMLSG 31-19/HOVON 501ChemotherapyChemo-substanceAzacitidineCytarabineDaunorubicinDecitabineDecitabine-CedazuridineGlasdegibImetelstatIvosidenibLenalidomideMelphalanVenetoclaxChemo-substanceAzacitidineCytarabineDaunorubicinDecitabineDecitabine-CedazuridineGlasdegibImetelstatIvosidenibLenalidomideMelphalanVenetoclaxChemo-substanceAzacitidineCytarabineDaunorubicinDecitabineDecitabine-CedazuridineGlasdegibImetelstatIvosidenibLenalidomideMelphalanVenetoclaxChemo-substanceAzacitidineCytarabineDaunorubicinDecitabineDecitabine-CedazuridineGlasdegibImetelstatIvosidenibLenalidomideMelphalanVenetoclaxNo. Substances123 RadiotherapySupportive therapySupportive substanceAciclovirAllopurinolAnti-thymocyte Globulin (Equine)Anti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiclosporin ACiprofloxacinCotrimoxazoleDarbepoetinDexamethasoneDimetindenEltrombopagEpoetin alfaFilgrastimFluconazoleFludarabineFosaprepitantGranisetronLevetiracetamLuspaterceptMelphalanMethylprednisoloneParacetamolPegfilgrastimPosaconazolePrednisoloneThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceAciclovirAllopurinolAnti-thymocyte Globulin (Equine)Anti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiclosporin ACiprofloxacinCotrimoxazoleDarbepoetinDexamethasoneDimetindenEltrombopagEpoetin alfaFilgrastimFluconazoleFludarabineFosaprepitantGranisetronLevetiracetamLuspaterceptMelphalanMethylprednisoloneParacetamolPegfilgrastimPosaconazolePrednisoloneThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceAciclovirAllopurinolAnti-thymocyte Globulin (Equine)Anti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiclosporin ACiprofloxacinCotrimoxazoleDarbepoetinDexamethasoneDimetindenEltrombopagEpoetin alfaFilgrastimFluconazoleFludarabineFosaprepitantGranisetronLevetiracetamLuspaterceptMelphalanMethylprednisoloneParacetamolPegfilgrastimPosaconazolePrednisoloneThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceAciclovirAllopurinolAnti-thymocyte Globulin (Equine)Anti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiclosporin ACiprofloxacinCotrimoxazoleDarbepoetinDexamethasoneDimetindenEltrombopagEpoetin alfaFilgrastimFluconazoleFludarabineFosaprepitantGranisetronLevetiracetamLuspaterceptMelphalanMethylprednisoloneParacetamolPegfilgrastimPosaconazolePrednisoloneThiotepaTreosulfanUrsodeoxycholic acidValaciclovirNo. Substances1235610111216Protocol classificationTherapy classificationalternativecurrent standardStudy protocol, currentIntensityKonditionierung, intensitäts- oder dosisreduziert (RIC)Konditionierung, myeloablativ (MAC)Konditionierung, nicht-myeloablativ (NMA)Low doseStandard doseTherapy indicationFirst lineRefractory diseaseRelapse therapyseveral possibleTherapy phaseallogene StammzelltransplantationConsolidationInductionTherapy intentioncurativecurative or palliativedisease controlpalliativesupportiveRisksAnemia Hb below 8g/dlAstheniaBleedingCardiotoxicityColitisConstipationDiarrheaDifferentiation syndromeDyspneaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaGastrointestinal ToxicityHeadacheHeart FailureHemorrhageHepatotoxicityHyperbilirubinemiaHypertensionHyponatremiaIncrease AminotransferasesInfectionsLeukopeniaNeurotoxicityNeutropeniaPainParesthesiaPneumoniaPyrexiaQTc Time ExtensionRashRenal FailureSepsisThrombocytopenia below 50 000/µlThromboembolic EventUpper Respiratory Tract InfectionVomiting only studiesPublicationAuthorBeelen DWCiurea SOCortes JECraddock CDiNardo CDDíez-Campelo MDöhner HEstey EFenaux PGarcia-Manero GGreenberg PHellström-Lindberg EKornblit BLübbert MMannone LMarks ROliva EN Park SPassweg JRPlatzbecker URambaldi ASasaki KSchroeder TShimoni AStasi RSteensma DStratmann JVillegas ADiseaseAML, 40-65 Jahre, ECOG 0-2, < 5% BlastenAML, MDS, CML, NHL, ungeeignet für konventionelle intensive KonditionierungAML- oder CMML-Rezidiv nach allogener StammzelltranplantationAML- oder MDS-Rezidiv nach allogener StammzelltranplantationAML/MDS, 18-65 Jahre, < 5% BlastenAML/MDS, 18-70 Jahre, AML in kompletter hämatologischer Remission (unter 5% Blasten) oder MDS (unter 20% Blasten), HCT-CI Score über 2AML/MDS, ALL, allogene StammzelltransplantationAML/MDS, allogene StammzelltransplantationAML/MDS, ungeeignet für konventionelle intensive KonditionierungAML/MDS, unter 55 JahreAML oder Hochrisiko MDS, nicht für eine Standard-Induktionschemotherapie geeignet, ECOG 0-2de-novo oder sekundäre AML, mindestens 1 nicht-kurative Vortherapie, über 65 JahreDe novo oder sekundäres myelodyplastisches Syndrom, alle Risikogruppen, ECOG 0-2Drohendes AML- oder MDS-Rezidiv nach allogener Stammzelltranplantation (Spenderchimärismus <80%)Hochrisiko myelodysplastisches Syndrom, ECOG 0-2Intermediär-1 und -2-Risiko oder Hochrisiko MDS, Alter > 60 Jahre, ECOG 0-2MDS, Hoch-Risiko, IDH-1-mutiert, therapierefraktär, ECOG 0-2MDS, Niedrig- oder Intermediär-1-Risiko, Deletion an Chromosom 5q, Anämie ohne TransfusionindikationMyelodysplastisches Syndrom, low/intermediate 1 risk, Lenalidomid naivMyelodysplastisches Syndrom, Niedrig-/Intermediär-1-Risiko, Thrombozytenwert unter 30.000/μl, ECOG 0-3Myelodysplastisches Syndrom, niedriges - intermediäres Risiko, Epo < 500 mU/mlMyelodysplastisches Syndrom, niedriges - intermediäres Risiko, Epo < 500 mU/ml, Hgb <10 g/dL, niedrige TransfusionsrateMyelodysplastisches Syndrom, niedriges - intermediäres Risiko, Epo < 500 mU/ml, niedrige Transfusionsrate, ECOG 0-1Myelodysplastisches Syndrom, Niedrigrisiko (low‐ oder intermediate‐1 risk) nach IPSSMyelodysplastisches Syndrom, Niedrigrisiko, ECOG 0-2Myelodysplastisches Syndrom mit refraktärer Anämie mit/ohne Sideroblasten, RAEB-I, oder hypoplastisch, ECOG 0-2Myelodysplastisches Syndrom und chronische myelomonozytäre Leukämie, ECOG 0-2Neu diagnostizierte AML oder MDS mit Blastenüberschuss-2, ECOG 0-2Niedrig- oder Intermediär-1-Risiko, singuläre Deletion an Chromosom 5q, transfusionspflichtige Anämieprimäres myelodysplastisches Syndrom länger als 6 Monate, nicht-transfundierter Hämoglobinwert < 10 g/dl, ECOG 0-2refraktäre Anämie, mit Sideroblasten oder exzessiven Blasten, nichtproliferative CMLrefraktäre Anämie beim myelodysplastischen Syndrom, niedrig-intermediäres Risiko, Epo < 500 mU/ml, niedrige TransfusionsrateTansfusionsabhängige Anämie bei MDS mit Ringsideroblasten, sehr niedriges, niedriges oder intermediäres Risiko nach IPSS-R, kein Ansprechen auf Erythropoetinbasierte Therapie oder nicht dafür geeignet OriginAlbert-Ludwigs University Medical Center, Freiburg, GermanyAlbert Ludwigs Universität, Freiburg, deutsche MDS- StudiengruppeARCADE trialAzienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy, EQoL-MDS trialCarl Gustav Carus Technical University of Dresden, Dresden, Germany, RELAZA trialClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WashingtonCollege of Medicine, Catholic University of Korea, Seoul, KoreaDepartment of Haematology, Nice University Hospital, Groupe Francais des Myelodysplasies (GFM)Department of Haematology and Oncology, Albert-Ludwigs University Medical Center, FreiburgDepartment of Hematology, Huddinge University Hospital, Huddinge, SwedenDepartment of Hematology, University Hospital Leipzig, Germany, IMergeDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, HoustonDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TXDepartment of Medical Sciences, Regina Apostolorum Hospital, Albano LazialeDivision Hematology and Oncology, University of Freiburg Medical Center, Freiburg, GermanyDivision of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TXHematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, ItalyHematology and Oncology, Goethe University, Frankfurt, Frankfurt am Main, GermanyHematology Department, Hospital Clinico San Carlos, Madrid, SpanienHopital Avicenne, Assistance Publique-Hôpitaux de Paris, Université Paris XIII, Bobigny, FranceHopital Saint-Louis, Assistance Publique-Hopitaux de Paris and Universite Paris 7, Paris, FranceHopitaux Universitaires de Geneve, Geneva, SAKK 33/99Hospital Universitario de Salamanca, Salamanca, Spain, SintraREV trialMayo Clinic Rochester, MN; Roswell Park Cancer Institute, Buffalo, NY, ADOPT trialOncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Duesseldorf, GermanyService d´Hematologie Clinique, Hoptial, Avicenne/Universite Paris, FranceStanford University Cancer Center, CA (ECOG E1996)The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, IsraelThe University of Texas M. D. Anderson Cancer Center, Houston, USAUlm University Hospital, Germany, AMLSG 31-19/HOVON 501University of Birmingham, Birmingham, United KingdomUniversity of Texas, MD Anderson Cancer Center, Houston, USAUniversity of Texas MD Anderson Cancer Center, Houston, USAWest German Cancer Centre, University of Duisburg-Essen, Essen, GermanyProtokolle in Überarbeitung 39 protocols foundAnti-thymocyte Globulin (Equine) 15 / Ciclosporin 5, Myelodysplastic Syndrome. (PID1766 V1.2)Azacitidine 100, Acute Myeloid Leukemia, and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplantation (PID2302 V1.0)Azacitidine 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplantation, Variant 1 (PID2320 V1.0)Azacitidine 75 / Lenalidomide 25, Acute Myeloid Leukemia and Myelodysplastic Syndrome following Allogeneic Stem Cell Transplantation (PID827 V1.2)Azacitidine 75, Acute Myeloid Leukemia, and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplantation (PID2327 V1.0)Azacitidine 75, Myelodysplastic Syndrome, High-Risk (PID616 V1.0)Azacitidine 75, Myelodysplastic Syndrome, Low risk (PID2317 V1.0)Azacitidine 75, Myelodysplastic Syndrome, Low risk, Variant 1 (PID3114 V1.0)Cytarabine 20 / Glasdegib 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome (PID1674 V1.0)Darbepoetin alfa 150, Myelodysplastic Syndrome (PID783 V1.0)Darbepoetin alfa 300 / Filgrastim 300, Myelodysplastic Syndrome (PID838 V1.0)Darbepoetin alfa 300, Myelodysplastic Syndrome (PID836 V1.0)Darbepoetin alfa 500, Myelodysplastic Syndrome (PID837 V1.0)Decitabine 15, Myelodysplastic Syndrome (PID727 V1.0)Decitabine 20, Myelodysplastic Syndrome (PID904 V1.0)Decitabine 20, Myelodysplastic Syndrome, Low risk (PID2318 V1.0)Decitabine-Cedazuridine 135, Myelodysplastic Syndrome (PID2514 V1.0)Eltrombopag 50, Myelodysplastic Syndrome (PID2513 V1.0)Epoetin Alfa 40000 / Filgrastim 120, Myelodysplastic Syndrome (PID728 V1.1)Epoetin Alfa 40000, Myelodysplastic Syndrome (PID841 V1.0)Fludarabine 30 / Carmustine 150 / Melphalan 110, Allogeneic Stem Cell Transplantation, RIC (PID880 V1.0)Fludarabine 30 / Carmustine 200 / Melphalan 140, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Allogeneic Stem Cell Transplantation, RIC (PID1705 V1.0)Fludarabine 30 / Melphalan 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Allogeneic Stem Cell Transplantation, RIC (PID3225 V1.0)Fludarabine 30 / TBI 2, Allogeneic Stem Cell Transplantation, NMA (PID3222 V1.0)Fludarabine 30 / Treosulfan 10, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Allogeneic Stem Cell Transplantation, MAC (PID1706 V1.0)Fludarabine 40 / Busulfan 0.8 / Anti-thymocyte Globulin (Rabbit) (0.5/2.0/2.5), Acute Myeloid Leukemia, Allogeneic Stem Cell Transplantation, MAC (PID885 V1.0)Fludarabine 40 / Busulfan 3.2 / Anti-thymocyte Globulin (Rabbit) 10, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Allogeneic Stem Cell Transplantation, MAC (PID881 V1.0)Imetelstat 7.1, myelodysplastic syndrome (PID2830 V1.0)Ivosidenib 500, Myelodysplastic Syndrome (PID2793 V1.0)Lenalidomide 10, Myelodysplastic Syndrome (PID118 V1.1)Lenalidomide 5, Myelodysplastic Syndrome (PID2700 V1.0)Luspatercept 1.0, Myelodysplastic Syndrome (PID1603 V1.0)Melphalan 140 / Thiotepa 10 / Fludarabine 40, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Allogeneic Stem Cell Transplantation, RIC (PID1738 V1.0)Melphalan 2, Acute Myeloid Leukemia, over 65 years of age (PID1735 V1.1)Study-AMLSG 31-19/HOVON 501 - Cytarabine 1000 / Venetoclax 400, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Induction II, over 60 years of age (PID3142 V1.0)Study-AMLSG 31-19/HOVON 501 - Cytarabine 1000 / Venetoclax 400, Acute Myeloid Leukemia and Myelodysplastic Syndrome, consolidation, over 60 years of age (PID3144 V1.0)Study-AMLSG 31-19/HOVON 501 - Cytarabine 1500 / Venetoclax 400, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Consolidation, under 60 years of age (PID3143 V1.0)Study-AMLSG 31-19/HOVON 501 - Daunorubicin 60 / Cytarabine 1000 / Venetoclax 400, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Induction II, under 60 years of age (PID3141 V1.0)Study-AMLSG 31-19/HOVON 501 - Daunorubicin 60 / Cytarabine 200 / Venetoclax (100/200/400), Acute Myeloid Leukemia and Myelodysplastic Syndrome, Induction I (PID3140 V1.0)
